Overseas revenue plummets, dragging down performance; the fundraising projects of Ota Biotechnology are delayed.

① Due to the impact of international situations, economic policies, and fluctuations in the overall market, the fundraising projects of Aotai Biological aimed at expanding overseas markets will be delayed. ② Overseas revenue has always been the most core source of income for Aotai Biological, with the overall income proportion once reaching 99.83%, and the sharp decline in overseas revenue has also led to a significant drop in Aotai Biological's overall income.

cls.cnDec 26 03:37 ET

The State Council meeting deployed to deepen the regulatory reform of Pharmaceutical and medical instruments, and Institutions indicated that there are significant structural opportunities in the Pharmaceutical Industry.

According to media reports, the recent State Council executive meeting deployed measures to deepen the regulation reform of pharmaceuticals and medical instruments, promoting the high-quality development of the pharmaceutical industry. Orient stated that looking back at 2024, the high base from the past has been digested, and the intra-hospital rigid demand is being released normally. Meanwhile, the Industry Chain of Innovative Drugs and the export of instruments continue to yield results, and the overall growth logic is clearly visible.

cls.cnDec 25 19:09 ET

The Byte Volcano Engine Developer Conference is about to begin, and the performance of domestic AI applications is expected to be rapidly released.

On December 19, the developer forum of the Volcanic Engine Winter FORCE Power Conference will be launched, focusing on the practices of the Volcanic Engine in the development, application, and implementation of large models. Northeast Securities' Wu Yuanheng believes that next year will be a significant year for domestic AI software and Hardware, driving rapid performance releases of related leading applications and Hardware companies.

cls.cnDec 17 19:01 ET

It is expected to fill the gap in the Global neonatal HIE treatment field, as Wanbangde Pharmaceutical Holding Group's subsidiary WP103 clinical trial application has been accepted by the FDA.

① Currently, no Pharmaceutical product containing Huperzine A has been approved for the market in the USA, and there are no approved drugs globally for the treatment of neonatal HIE. ② Multiple preclinical studies have shown that Huperzine A has significant potential for treating neonatal HIE, with the hope of addressing the pathophysiological challenges of hypoxia-ischemia through a comprehensive mechanism of action.

cls.cnDec 17 09:51 ET

Shanghai Sanyou Medical Co., Ltd acquires its controlling subsidiary at a 4 times premium, with the necessity of the Trade and performance commitments being key points of inquiry.

① Shanghai Sanyou Medical Co., Ltd intends to acquire the remaining shares of its subsidiary, Shuimu Tianpeng. An assessment indicates that Shuimu Tianpeng's value has increased by 0.693 billion yuan, with a value increase rate of 406.21%. ② Shanghai Sanyou Medical Co., Ltd stated that the acquisition is beneficial for enhancing the company's overall profitability. Prior to the acquisition, Shanghai Sanyou Medical Co., Ltd had consistently faced declining performance.

cls.cnDec 17 05:18 ET

After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?

① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.

cls.cnDec 13 03:28 ET